Clinical review on triglycerides

Abstract Hypertriglyceridaemia is a common clinical problem. Epidemiologic and genetic studies have established that triglyceride-rich lipoproteins (TRL) and their remnants as important contributors to ASCVD while severe hypertriglyceridaemia raises risk of pancreatitis. While low-density lipoprotei...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal 2020-01, Vol.41 (1), p.99-109c
Main Authors: Laufs, Ulrich, Parhofer, Klaus G, Ginsberg, Henry N, Hegele, Robert A
Format: Article
Language:English
Subjects:
Clinical Review
Humans
Hypertriglyceridemia - therapy
Life Style
Triglycerides
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c498t-d8b6bd8995633cdf0de64db6cb361cf1ae306bfe0f75b8aeead57c226ce13a4f3
cites cdi_FETCH-LOGICAL-c498t-d8b6bd8995633cdf0de64db6cb361cf1ae306bfe0f75b8aeead57c226ce13a4f3
container_end_page 109c
container_issue 1
container_start_page 99
container_title European heart journal
container_volume 41
creator Laufs, Ulrich
Parhofer, Klaus G
Ginsberg, Henry N
Hegele, Robert A
description Abstract Hypertriglyceridaemia is a common clinical problem. Epidemiologic and genetic studies have established that triglyceride-rich lipoproteins (TRL) and their remnants as important contributors to ASCVD while severe hypertriglyceridaemia raises risk of pancreatitis. While low-density lipoprotein is the primary treatment target for lipid lowering therapy, secondary targets that reflect the contribution of TRL such as apoB and non-HDL-C are recommended in the current guidelines. Reduction of severely elevated triglycerides is important to avert or reduce the risk of pancreatitis. Here we discuss interventions for hypertriglyceridaemia, including diet and lifestyle, established treatments such as fibrates and omega-3 fatty acid preparations and emerging therapies, including various biological agents.
doi_str_mv 10.1093/eurheartj/ehz785
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6938588</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurheartj/ehz785</oup_id><sourcerecordid>2317961020</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-d8b6bd8995633cdf0de64db6cb361cf1ae306bfe0f75b8aeead57c226ce13a4f3</originalsourceid><addsrcrecordid>eNqFkD1PwzAQhi0EoqWwM6GOSCjUjuOLvSChii-pEgtIbJbjXFpXaVLspKj8eoJSKpiYbrjnnrt7CTln9JpRxSfY-gUa3ywnuPhMpTggQybiOFKQiEMypEyJCEC-DchJCEtKqQQGx2TAWQqJkjAk42npKmdNOfa4cfgxrqtx49283Fr0LsdwSo4KUwY829UReb2_e5k-RrPnh6fp7SyynaiJcplBlkulBHBu84LmCEmegc04MFswg5xCViAtUpFJg2hykdo4BouMm6TgI3LTe9dttsLcYtV4U-q1dyvjt7o2Tv_tVG6h5_VGg-JSSNkJLncCX7-3GBq9csFiWZoK6zbouHtaAaMx7VDao9bXIXgs9msY1d_B6n2wug-2G7n4fd5-4CfJDrjqgbpd_6_7AiBciOM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2317961020</pqid></control><display><type>article</type><title>Clinical review on triglycerides</title><source>Oxford Journals Online</source><creator>Laufs, Ulrich ; Parhofer, Klaus G ; Ginsberg, Henry N ; Hegele, Robert A</creator><creatorcontrib>Laufs, Ulrich ; Parhofer, Klaus G ; Ginsberg, Henry N ; Hegele, Robert A</creatorcontrib><description>Abstract Hypertriglyceridaemia is a common clinical problem. Epidemiologic and genetic studies have established that triglyceride-rich lipoproteins (TRL) and their remnants as important contributors to ASCVD while severe hypertriglyceridaemia raises risk of pancreatitis. While low-density lipoprotein is the primary treatment target for lipid lowering therapy, secondary targets that reflect the contribution of TRL such as apoB and non-HDL-C are recommended in the current guidelines. Reduction of severely elevated triglycerides is important to avert or reduce the risk of pancreatitis. Here we discuss interventions for hypertriglyceridaemia, including diet and lifestyle, established treatments such as fibrates and omega-3 fatty acid preparations and emerging therapies, including various biological agents.</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehz785</identifier><identifier>PMID: 31764986</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Clinical Review ; Humans ; Hypertriglyceridemia - therapy ; Life Style ; Triglycerides</subject><ispartof>European heart journal, 2020-01, Vol.41 (1), p.99-109c</ispartof><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology. 2019</rights><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c498t-d8b6bd8995633cdf0de64db6cb361cf1ae306bfe0f75b8aeead57c226ce13a4f3</citedby><cites>FETCH-LOGICAL-c498t-d8b6bd8995633cdf0de64db6cb361cf1ae306bfe0f75b8aeead57c226ce13a4f3</cites><orcidid>0000-0003-2620-9323 ; 0000-0001-9873-0412 ; 0000-0003-2861-5325</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31764986$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Laufs, Ulrich</creatorcontrib><creatorcontrib>Parhofer, Klaus G</creatorcontrib><creatorcontrib>Ginsberg, Henry N</creatorcontrib><creatorcontrib>Hegele, Robert A</creatorcontrib><title>Clinical review on triglycerides</title><title>European heart journal</title><addtitle>Eur Heart J</addtitle><description>Abstract Hypertriglyceridaemia is a common clinical problem. Epidemiologic and genetic studies have established that triglyceride-rich lipoproteins (TRL) and their remnants as important contributors to ASCVD while severe hypertriglyceridaemia raises risk of pancreatitis. While low-density lipoprotein is the primary treatment target for lipid lowering therapy, secondary targets that reflect the contribution of TRL such as apoB and non-HDL-C are recommended in the current guidelines. Reduction of severely elevated triglycerides is important to avert or reduce the risk of pancreatitis. Here we discuss interventions for hypertriglyceridaemia, including diet and lifestyle, established treatments such as fibrates and omega-3 fatty acid preparations and emerging therapies, including various biological agents.</description><subject>Clinical Review</subject><subject>Humans</subject><subject>Hypertriglyceridemia - therapy</subject><subject>Life Style</subject><subject>Triglycerides</subject><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNqFkD1PwzAQhi0EoqWwM6GOSCjUjuOLvSChii-pEgtIbJbjXFpXaVLspKj8eoJSKpiYbrjnnrt7CTln9JpRxSfY-gUa3ywnuPhMpTggQybiOFKQiEMypEyJCEC-DchJCEtKqQQGx2TAWQqJkjAk42npKmdNOfa4cfgxrqtx49283Fr0LsdwSo4KUwY829UReb2_e5k-RrPnh6fp7SyynaiJcplBlkulBHBu84LmCEmegc04MFswg5xCViAtUpFJg2hykdo4BouMm6TgI3LTe9dttsLcYtV4U-q1dyvjt7o2Tv_tVG6h5_VGg-JSSNkJLncCX7-3GBq9csFiWZoK6zbouHtaAaMx7VDao9bXIXgs9msY1d_B6n2wug-2G7n4fd5-4CfJDrjqgbpd_6_7AiBciOM</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Laufs, Ulrich</creator><creator>Parhofer, Klaus G</creator><creator>Ginsberg, Henry N</creator><creator>Hegele, Robert A</creator><general>Oxford University Press</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2620-9323</orcidid><orcidid>https://orcid.org/0000-0001-9873-0412</orcidid><orcidid>https://orcid.org/0000-0003-2861-5325</orcidid></search><sort><creationdate>20200101</creationdate><title>Clinical review on triglycerides</title><author>Laufs, Ulrich ; Parhofer, Klaus G ; Ginsberg, Henry N ; Hegele, Robert A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-d8b6bd8995633cdf0de64db6cb361cf1ae306bfe0f75b8aeead57c226ce13a4f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Clinical Review</topic><topic>Humans</topic><topic>Hypertriglyceridemia - therapy</topic><topic>Life Style</topic><topic>Triglycerides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Laufs, Ulrich</creatorcontrib><creatorcontrib>Parhofer, Klaus G</creatorcontrib><creatorcontrib>Ginsberg, Henry N</creatorcontrib><creatorcontrib>Hegele, Robert A</creatorcontrib><collection>Oxford Open</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Laufs, Ulrich</au><au>Parhofer, Klaus G</au><au>Ginsberg, Henry N</au><au>Hegele, Robert A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical review on triglycerides</atitle><jtitle>European heart journal</jtitle><addtitle>Eur Heart J</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>41</volume><issue>1</issue><spage>99</spage><epage>109c</epage><pages>99-109c</pages><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Abstract Hypertriglyceridaemia is a common clinical problem. Epidemiologic and genetic studies have established that triglyceride-rich lipoproteins (TRL) and their remnants as important contributors to ASCVD while severe hypertriglyceridaemia raises risk of pancreatitis. While low-density lipoprotein is the primary treatment target for lipid lowering therapy, secondary targets that reflect the contribution of TRL such as apoB and non-HDL-C are recommended in the current guidelines. Reduction of severely elevated triglycerides is important to avert or reduce the risk of pancreatitis. Here we discuss interventions for hypertriglyceridaemia, including diet and lifestyle, established treatments such as fibrates and omega-3 fatty acid preparations and emerging therapies, including various biological agents.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>31764986</pmid><doi>10.1093/eurheartj/ehz785</doi><orcidid>https://orcid.org/0000-0003-2620-9323</orcidid><orcidid>https://orcid.org/0000-0001-9873-0412</orcidid><orcidid>https://orcid.org/0000-0003-2861-5325</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0195-668X
ispartof European heart journal, 2020-01, Vol.41 (1), p.99-109c
issn 0195-668X
1522-9645
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6938588
source Oxford Journals Online
subjects Clinical Review
Humans
Hypertriglyceridemia - therapy
Life Style
Triglycerides
title Clinical review on triglycerides
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A40%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20review%20on%20triglycerides&rft.jtitle=European%20heart%20journal&rft.au=Laufs,%20Ulrich&rft.date=2020-01-01&rft.volume=41&rft.issue=1&rft.spage=99&rft.epage=109c&rft.pages=99-109c&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehz785&rft_dat=%3Cproquest_pubme%3E2317961020%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c498t-d8b6bd8995633cdf0de64db6cb361cf1ae306bfe0f75b8aeead57c226ce13a4f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2317961020&rft_id=info:pmid/31764986&rft_oup_id=10.1093/eurheartj/ehz785&rfr_iscdi=true